Biosimilars Pathway Dilemma: When Should Sponsors Pick (k) Before (a)?

Extrapolation and interchangeability appear to be the linchpins for biosimilar sponsors mulling whether to send applications to the emerging 351(k) pathway or the traditional novel biologics approval system.